The mission of EpiPredict is to train a multidisciplinary cohort of young researchers in a new approach to fully exploit the epigenetics of complex diseases. The 12 early-stage researchers (ESRs) will focus on a narrowly defined case, Tamoxifen-induced resistance in Estrogen Receptor positive (ER+) breast cancer, considering five interacting resistance pathways. Read more...


Please visit our news page for the latest announcements and press or our Facebook or Twitter pages!


EpiPredict scientists discover novel mechanism behind underlying breast cancer hormone therapy resistance


An international team of researchers, including EpiPredict researchers, discovered a mechanism that makes a common type of breast cancer cells resistant to a specific form of hormone treatment. This was published online in Nature Genetics, 23 Jan 2017.

Read more

First EpiPredict blog published in Medium 'From Lab bench to Bed'


Will Beckman (ESR3, UvA) together with EpiPredict Partner Organisation Biotecture wrote a blog in Medium, ‘From Lab bench to Bed, How understanding epigenetics could benefit breast cancer patients’.

Read more



EpiPredict science cafe

Imperial College London - London, United Kingdom, December 2017

Second EpiPredict Science Café

Imperial College London, UK, Friday 15 December, 2017

Further information will follow...